SGH
PVCT

Schonfeld Group Holdings’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Schonfeld Group Holdings’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,000
Closed -$12K – 81
2015
Q1 		$12K Buy
+15,000
New +$12.4K 0.09% 22

Other funds holding PVCT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Schonfeld Group Holdings's PVCT Position: Q2 2015 in Review

Schonfeld Group Holdings sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q2 2015, closing a stake of 15,000 shares — an estimated $12K sold.

Schonfeld Group Holdings first reported a position in PVCT in Q1 2015 and held it in 1 quarter. The position peaked at $12K in Q1 2015. 36 funds tracked by Wall St. Rank hold PVCT as of Q2 2015.

  • Schonfeld Group Holdings reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q2 2015 after selling out during the quarter.
  • Schonfeld Group Holdings sold 15,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q2 2015, an estimated $12K.
  • Schonfeld Group Holdings first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q1 2015 and held it in 1 quarter.
  • Schonfeld Group Holdings's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $12K in Q1 2015.
  • 36 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q2 2015.

Based on Schonfeld Group Holdings's 13F filing for Q2 2015, filed 14 Aug 2015.